Sobi gets EU nod for Doptelet in rare blood disorder ITPSweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the Share XSobi gets EU nod for Doptelet in rare blood disorder ITPhttps://pharmaphorum.com/news/sobi-gets-eu-nod-for-doptelet-in-rare-blood-disorder-itp/
Roche set to file ophthalmology drug faricimab in DMERoche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody Share XRoche set to file ophthalmology drug faricimab in DMEhttps://pharmaphorum.com/news/roche-set-to-file-ophthalmology-drug-faricimab-in-dme/
FDA rejects Novartis’ cholesterol drug after factory inspection issueNovartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster Share XFDA rejects Novartis’ cholesterol drug after factory inspection issuehttps://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/
Novartis buys neurology biotech Cadent for up to $770mNovartis is to buy neuroscience drugs firm Cadent Therapeutics in a deal worth up to $770 million. The Share XNovartis buys neurology biotech Cadent for up to $770mhttps://pharmaphorum.com/news/novartis-buys-neurology-biotech-cadent-for-up-to-770m/
Entresto set for big sales hike after FDA panel endorsementNovartis’ Entresto is on course to become the first drug to be approved in the US for a Share XEntresto set for big sales hike after FDA panel endorsementhttps://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement/
Novartis/Incyte draw blank with Jakafi in COVID-19Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against Share XNovartis/Incyte draw blank with Jakafi in COVID-19https://pharmaphorum.com/news/novartis-incyte-draw-blank-with-jakafi-in-covid-19/
Novartis signs ophthalmology AI deal with RetinAINovartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial Share XNovartis signs ophthalmology AI deal with RetinAIhttps://pharmaphorum.com/news/novartis-signs-ophthalmology-ai-d/
Novartis set to overcome $14 billion patent cliff say analystsNovartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition Share XNovartis set to overcome $14 billion patent cliff say analystshttps://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/
Novartis taps smartpatient for app to support wet AMD patientsGerman digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet Share XNovartis taps smartpatient for app to support wet AMD patientshttps://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/
